How pharma economics hold back antibiotic development
Dick Jenkins and other ‘angel’ investors have committed more than £20mn to the development of an experimental drug to tackle life-threatening infections. But they have come up against a substantial hurdle: a need for even more money.
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!